ScinoPharm Taiwan, Ltd.

TWSE:1789 Stock Report

Market Cap: NT$18.1b

ScinoPharm Taiwan Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Susan Lu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.1yrs
CEO ownershipn/a
Management average tenure4.5yrs
Board average tenure7.1yrs

Recent management updates

Recent updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Apr 04
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Mar 14
A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

Feb 21
Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

Jan 25
ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Jan 04
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Dec 14
Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Nov 23
Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

CEO

Susan Lu

4.1yrs

Tenure

Ms. Li-An Lu, also known as Susan, is Director of SciAnda (Changshu) Pharmaceutical, Ltd. from June 14, 2024. She serves as President and Chief Executive Officer at ScinoPharm Taiwan, Ltd.since 2021. She...

Leadership Team

NamePositionTenureCompensationOwnership
Chih-Hsien Lo
Chairman & General Chief Strategy Officer14.6yrsno datano data
Li-An Lu
President & CEO4.1yrsno datano data
Chih-Hui Lin
Acting Financial Off.14.7yrsno datano data
Ling-Hsiao Lien
Vice-President of Marketing4.5yrsno datano data
Li-Chiao Chang
VP of R&D Division and Chief Scientific Officerno datano data0%
NT$ 0
Jason Chen
Director of Human Resources & Admin3.7yrsno datano data
Shun Yang Lin
Director of Corporate Developmentno datano datano data

4.5yrs

Average Tenure

Experienced Management: 1789's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chih-Hsien Lo
Chairman & General Chief Strategy Officer14.6yrsno datano data
Po-Ming Hou
Representative Director8.3yrsno datano data
Fu-Jung Lai
Representative Director6.3yrsno datano data
Shiow-Ling Kao
Representative Director14.6yrsno datano data
Chiou-Ru Shih
Representative Director14.6yrsno datano data
Tsung-Ping Wu
Representative Director9.7yrsno datano data
Jia-Horng Guo
Representative Director7.5yrsno datano data
Li-Tzong Chen
Independent Director6.7yrsno datano data
Ming-Chuan Hsieh
Representative Director6.7yrsno datano data
Ya-Po Yang
Representative Director6.7yrsno datano data
Wen-Chang Chang
Independent Director6.7yrsno datano data
Lewis Lee
Independent Director4.1yrsno datano data

7.1yrs

Average Tenure

Experienced Board: 1789's board of directors are considered experienced (7.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 15:52
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ScinoPharm Taiwan, Ltd. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ti-Rung HuangBarclays
Pinghan HsiehCapital Securities Corporation
Christine WangDaiwa Securities Co. Ltd.